Werewolf Therapeutics, Inc.
HOWLNasdaqCIK 1785530HealthcareFiscal year ends Dec 31
Reports and events: 103 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-2109:10 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-360059 |
| 2026-08-2016:06 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-26-359185 |
| 2026-07-3107:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001785530-26-000019 |
| 2026-07-3107:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-26-000018 |
| 2026-07-0220:26 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000187 |
| 2026-06-2617:39 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000185 |
| 2026-06-2219:02 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000180 |
| 2026-06-1520:16 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000175 |
| 2026-05-1417:23 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000131 |
| 2026-05-1219:56 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001609492-26-000006 |
| 2026-05-0716:14 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001785530-26-000012 |
| 2026-05-0716:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-26-000011 |
| 2026-05-0519:04 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001609492-26-000004 |
| 2026-03-2707:12 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001785530-26-000006 |
| 2026-03-2707:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-26-000005 |
| 2026-02-2417:26 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-067569 |
| 2026-02-1316:20 ET | 8-K | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001193125-26-051455 |
| 2026-02-0616:41 ET | 8-K | 3.01 Delisting notice | 0001193125-26-041305 |
| 2026-01-1617:36 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001609492-26-000002 |
| 2025-12-2918:59 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001231919-25-000666 |
| 2025-12-1808:24 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-323787 |
| 2025-12-0319:04 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001231919-25-000570 |
| 2025-11-1720:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001231919-25-000511 |
| 2025-11-0616:29 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-25-000040 |
| 2025-11-0418:33 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001231919-25-000422 |
| 2025-11-0407:11 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001785530-25-000031 |
| 2025-11-0407:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-25-000030 |
| 2025-10-0616:33 ET | 8-K | 3.01 Delisting notice | 0001193125-25-231953 |
| 2025-08-1407:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001785530-25-000021 |
| 2025-08-1407:06 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001785530-25-000020 |
| 2025-06-1316:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-25-140727 |
| 2025-05-1517:00 ET | 8-K | 3.01 Delisting notice | 0001193125-25-120910 |
| 2025-05-1418:09 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001415889-25-012944 |
| 2025-05-0807:10 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001785530-25-000014 |
| 2025-05-0807:06 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001785530-25-000013 |
| 2025-04-2807:58 ET | DEF 14A | Proxy statementPeriod 2025-06-12 | 0001140361-25-015885 |
| 2025-03-1107:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001785530-25-000008 |
| 2025-03-1107:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-25-000006 |
| 2025-02-2407:49 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-032804 |
| 2024-11-1207:45 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-255170 |
| 2024-11-0709:09 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001785530-24-000034 |
| 2024-11-0709:06 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001785530-24-000033 |
| 2024-08-0807:12 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001785530-24-000028 |
| 2024-08-0807:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-24-000026 |
| 2024-06-2507:07 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-167467 |
| 2024-06-0307:56 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-152380 |
| 2024-05-2816:27 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-148114 |
| 2024-05-0716:52 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-058078 |
| 2024-05-0307:10 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001785530-24-000020 |
| 2024-05-0307:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001785530-24-000018 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 17:25 ET. Listed shows no prices and gives no investment advice.